
Opinion|Videos|July 9, 2024
Treatment Options for Spasticity
A panel of experts discuss treatment options available for spasticity as well as when patients should be treated with pharmacological options.
Advertisement
Episodes in this series

- Discuss treatment options available for spasticity. How is spasticity managed upon initial clinical presentation?
- When should patients be treated with pharmacological options? Surgical options?
- Botulinum toxin (BT) injections are used widely to treat focal spasticity. When and in which patients are BT injections recommended?
- When would you use or need multiple approaches to treat spasticity?
Advertisement
Related to this article

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of neurology!

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
2
Remibrutinib Phase 3 Results in RMS, Blood Pressure Variability Findings, and Updated Stroke Rehabilitation Guidelines
3
How MS Understanding Has Evolved: Activity, Impact, and Progression
4
Distinguishing Lambert-Eaton Myasthenic Syndrome From Myasthenia Gravis: Ocular and Systemic Clues
5


